Abstract
Actinic keratoses are quite common. Since they represent the initial stage in the evolution of squamous cell carcinoma, recognition and treatment are important. Recently, new treatment modalities have become available including immune modulators, photodynamic therapy, and topical nonsteroidal anti-inflammatory agents.
Similar content being viewed by others
References
Stockfleth E, Meyer T, Benninghoff B, et al. Successful treatment of actinic keratosis with imiquimod cream 5%: A report of six cases. Br J Dermatol. 2001;144:1050–3.
Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994;131:455–64.
Lober BA, Lober CW. Actinic keratosis is squamous cell carcinoma. South Med J. 2000;7:650–5.
Engel A, Johnson ML, Haynes SG. Health effects of sunlight exposure in the United States: Results from the first national health and nutrition examination survey 1971–4. Arch. Dermatol. 1988;124:72–9.
Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:S4-S7.
Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:S8-S10.
Schwartz RA. The actinic keratosis: A perspective and update. Dermatol Surg. 1997;23:1009–19.
Jeffes EWB III, Tang EH. Actinic keratosis. Current treatment options. Am J Clin Dermatol. 2002;3:167–79.
Bavinck JN, DeBoer A, Vermeer BJ, et al. Sunlight, keratotic skin lesions, and skin cancer in renal transplant recipients. Br J Dermatol. 1993;129:242–9.
Tucci MG, Offidani A, Lucarini G, et al. Advances in the understanding of malignant transformation of keratinocytes: An immunohistochemical study. J Eur Acad Dermatol Venereol. 1998;10:118–24.
Van Praag MC, Bavinick JN, Bergman W, et al. PUVA keratosis. A clinical and histopathologic entity associated with an increased risk of non-melanoma skin cancer. J Am Acad Dermatol. 1993;28:412–7.
Wolf JE Jr, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709–13.
Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:S23-S24.
Dobson JM, DeSpain J, Hewett JE, et al. Malignant potential of actinic keratoses and controversy over treatment: A patient-oriented perspective. Arch Dermatol. 1991;127:1029–31.
Cockrell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma (actinic keratosis). J Am Acad Dermatol. 2000;42:S11-S17.
Ziegler A, Jonason AS, Lefell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature. 1994;372:773–6.
Nelson MA, Eiknspahr JG, Alberto DS, et al. Analysis of p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett. 1991;85:23–9.
Marks R, Ronnie G, Selwood TS. Malignant transformation of solar keratosis to squamous cell carcinoma. Lancet. 1988; I:795–7.
Farmer KC, Naylor MF. Sun exposure, sunscreens, and skin cancer prevention: A year round concern. Ann Pharmacother. 1996;30:662–73.
Marks R, Motley RJ. Skin cancer: recognition and treatment. Drugs. 1995;50:48–61.
Marks R, Foley P, Goodman G, et al. Spontaneous reminsion of solar keratosis: The case for conservative management. Br J Dermatol. 1986;115:649–55.
Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000;42:S25-S28.
Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol. 1982;7:631–2.
Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses. An update and comparison. Dermatol Surg. 2000;8:728–32.
Schwartz RA. Therapeutic perspective in actinic and other keratoses. Int J Dermatol. 1996;35:533–8.
Kuflik EG. Cryosurgery updated. J Am Acad Dermatol. 1994;31:925–34.
Goette DK. Topical chemotherapy with 5 fluoracil. A review. J Am Acad Dermatol. 1981;4:633–49.
Robinson TA, Kligman AM. Treatment of solar keratoses of the extremities with retinoic acid and 5-flurouracil. Br J Dermatol. 1975;92:703–6.
Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-flurouracil: A double-blind controlled study. Br J Dermatol. 1987;116:549–52.
Epstein E. Does intermittent pulse topical 5 flurouracil therapy allow destruction of actinic keratoses without significant inflammation J Am Acad Dermatol. 1998;38:77–80.
Lawrence N, Cox SE, Clay J, et al. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluoracil in the treatment of widespreac facial actinic keratoses. Arch Dermatol. 1995;131:176–81.
Coleman WP, Yarborough JM, Mandy SH, Dermabrasion for prophylaxis and treatment of actinic keratosis. Dermatol. Surg. 1996;22:17–21.
Fitzpatrick R, Goldman MP, Satur NM, et al. Pulsed carbon dioxide laser resurfacing of photo damaged skin. Arch Dermatol. 1996;132:395–402.
Spicer MS, Goldberg DJ. Lasers in dermatology. J Am Acad Dermatol. 1996;34:1–25.
Jeffes EWB, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratoses with topical 5-aminolevulonic acid. A pilot dose-ranging study. Arch Dermatol. 1997; 133:727–32.
Kurwa HA, Yong-Gee SA, Seed PT, et al. A randomized paired comparison of photodynamic therapy and topical 5-flurouracil in the treatment of actinic keratosis. J Am Acad Dermatol. 1999;41:414–8.
Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999; 41:1002–7.
Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol. 1997;133:1239–42.
Peters DC, Foster RH. Diclofenac/hyaluronic acid. Drugs Aging. 1999;14:313–21.
Dufresne RG, Curlin MU. Actinic cheilitis: a treatment review. Dermatol Surg. 1997;23:15–21.
Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl Med J. 1993;329: 1147–51.
Naylor MF, Boyd A, Smith DW, et al. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol. 1995;131:170–5.
Kligman AM, Thorne EG. Topical therapy of actinic keratoses with tretino. In: Marks R, ed. Retinoids in Cutaneous Malignancy. Oxford, Blackwell Scientific Publications; 1991:66–73.
Author information
Authors and Affiliations
Additional information
Pearon G. Lang, MD, Professor of Dermatology, Pathology, Otolaryngology and Communicative Sciences and Director of Mohs Surgery and Cutaneous Oncology and Diermatological Surgery.
The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article. The authors also do not discuss the use of off-label products, which includes unlabeled, unaproved, or investigative products or devices.
About this article
Cite this article
Lang, P.G. Management of actic keratoses. Compr Ther 29, 108–114 (2003). https://doi.org/10.1007/s12019-003-0014-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s12019-003-0014-7